Procalcitonin as a Marker of Bacterial Pneumonia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00415753|
Recruitment Status : Completed
First Posted : December 25, 2006
Last Update Posted : May 23, 2008
Objective: To evaluate PCT as a marker of bacterial community acquired pneumonia in a Danish Hospital setting. To test if it is possible to reduce the use of antibiotics and the length of stay in hospital, and the willingness of the clinicians to take this new marker under advisement in their choice of treatment.
The study is a randomised, controlled intervention study. All adult patients admitted to the Department of Infectious Disease at Skejby hospital suspected of a lower respiratory tract infection (e.g. CAP, acute exacerbation of COPD and bronchitis) are eligible for inclusion. Patients are randomised to have either PCT guided treatment or standard care, in which case the doctor will not learn the PCT test result. In the PCT group the antibiotic treatment will be based on serum PCT as follows: If PCT is less than 0.25 µg/L antibiotic treatment is discouraged; if PCT is greater than 0.25 µg/L antibiotic treatment is encouraged and if PCT is greater than 0.5 µg/L antibiotic treatment is strongly encouraged. The treating doctor is allowed to overrule the treatment guidelines. The control group will receive antibiotics according to usual practice.
The primary endpoints are antibiotic use and length of stay in hospital. Secondary endpoint is the proportion of patients where the treating doctor chooses to disregard the guidelines.
|Condition or disease||Intervention/treatment||Phase|
|Pneumonia Bronchitis COPD||Behavioral: No antibiotics if se-procalcitonin is below stated limit||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||223 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||June 2006|
|Actual Primary Completion Date :||April 2007|
|Actual Study Completion Date :||August 2007|
- Antibiotic use
- Length of stay in hospital
- The proportion of patients where the doctor chooses to disregard treatment guidelines
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00415753
|Department of Infectious Diseases, Skejby Hospital|
|Aarhus N, Denmark, 8200|
|Departement of Medicin, Silkeborg Hospital|
|Silkeborg, Denmark, 8600|
|Study Chair:||Finn T Black, Professor||Aarhus Universityhospital|
|Principal Investigator:||Kristina B Kristoffersen||Aarhus University Hospital Skejby|